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1306 Chronic heart failure (CHF)
MAPK; PI3K-AKT pathways on mRNA levels (RTPCR) also HER2 on protein level
(ELISA; ng HER2/ 1g total protein) were performed.
Results: The HER2 expression on the protein level was reduced in HF vs NFH
both in LV (p<0.0001, 3,1±0,55 vs 13,48±3,93, respectively) and RV (p<0.0001,
2,83±0,47 vs 17,43±5,58). The expression on mRNA level was also importantly
changed in HF vs NFH both LV and RV with regard to HER4; RAS; MAPK; PI3K.
Conclusions: Despite impressive efficacy of HER2 inhibition in oncology treat-
ment, even in clinically stable patients with past HF history, the modification of hu-
man hearts HER2 pathways could be potentially unsafe during the use of HER2
inhibitors. So the thorough initial assessment and close monitoring during treat-
ment period should be maintained.
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Anthracycline cardiotoxicity in patients with acute myeloid leukemia:
cardiovascular risk assessment, monitoring and management
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Introduction: Cardiotoxicity of anthracyclines during treatment for acute myelo-
cytic leukemia (AML) remains a significant cause of mortality. Close monitoring of
cardiac function and risk factor management is crucial for early recognition and
treatment, although not mandated by current guidelines.
Methods: The study included 55 patients with AML who received induction
anthracycline-based chemotherapy between February 1, 2007 and March 1,
2015. Cardiotoxicity was defined as a decrease in the left ventricular ejection
fraction (LVEF) of >10%, to a value <53%. We also evaluated Sorror Index (SI)
a risk assessment tool before allogeneic transplant. SI>2 determines high risk of
mortality.
Results: The mean age was 58 years and 49.1% were females. Overall 13
(23.6%) of the 55 patients who received chemotherapy treatment developed car-
diotoxicity: 7 (12.7%) - permanent decrease of LVEF, 6 (10.9%) – transient LVEF
decrease with subsequent improvement to baseline. SI >2 was observed in five
of seven patients with permanent LVEF decrease, while in group of patients with
transient LVEF decrease only in one case SI was >2.
Only three of seven patients with permanent LVEF decrease after chemother-
apy were treated with beta-blockers (BB), ACEi/ARB and MRA. Only two of six
patients with a temporary decrease in EF were on these disease-modifying med-
ications. Five of thirteen patients with cardiotoxicity were not even referred for
cardiology follow-up.
Conclusion: Not all patients who met criteria for cardiotoxicity with left ventricu-
lar dysfunction (LVD) were initiated on optimal heart failure medications nor seen
by a cardiologist. The implementation of a standard protocol for cancer patients
receiving cardiotoxic medications may enable better detection and early manage-
ment of LVD before the onset of clinical heart failure. Sorror index may be used to
determine subgroup of patients who may be given prophylactic “cardioprotective”
therapy.
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Introduction: Chemotherapy-induced cardiotoxicity is a growing concern. The
true cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is un-
known, especially the ones used for chronic myeloid leukaemia. We aim to eval-
uate nilotinib and imatinib induced cardiotoxicity.
Methods: Single-center prospective study of consecutive patients with chronic
myeloid leukaemia treated with tyrosine kinase inhibitors during 2015. Patients
underwent an initial clinical, laboratorial and echocardiographic evaluation, re-
peated one year after therapy initiation.
Results: Eleven patients were included [60.0 (11) years, 63.6% of males; 7 pa-
tients treated with imatinib and 4 with nilotinib]. After one year of follow-up, all pa-
tients remained in functional NYHA class I, with a similar Minnesota quality of life
score [21 (20) vs. 21 (19), p = NS]. Also there was no difference in the biomarkers
evaluated: cystatin-C [0.9 (0.2) vs. 0.8 (0.2) mg/L, p = NS; NT-proBNP 46.0 (45.0)
vs. 42.0 (34.0) pg/mL, p = NS]. Previous to the TKI treatment, all patients had
normal left ventricular ejection fraction (LVEF) [(median 67% (63–69)], without
structural abnormalities. During the follow-up, there weren’t differences regarding
the LVEF, left atrium volume, E/A ratio, deceleration time, septal e’, lateral e’, E/e’
ratio and tricuspid annular plane systolic excursion. With regard to myocardial de-
formation, all patients presented normal values of longitudinal, circumferential and
radial strain in the baseline study, without changes during follow-up [DML -21.3
(6, 1) vs. -21.7 (6.0)%, p = NS; DMC -20.0 (9.3) vs. -22.3 (5.3)%, p = NS; DMR
36.9 (21.3) vs. 39.2 (19.2)%, p = NS]. In addition, there were no differences be-
tween the two tyrosine kinase inhibitors used, considering all the aforementioned
variables.
Conclusion: No clinical, laboratory or echocardiographic evidence of nilotinib
and imatinib induced cardiotoxicity was observed, even when myocardial de-
formation analysis was performed. However, these results should be confirmed
in larger studies, ideally multicentre, given the low incidence of chronic myeloid
leukaemia.
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Impact of left ventricular function in coronary artery disease patients
with and without diabetes. Long-term follow-up - REVISION-DM2 Trial
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Background: It is assumed that the left ventricular dysfunction due to ischemic
cardiomyopathy is a major determinant of poor prognosis of survival when com-
pared to preserved ventricular function. However, it is unknown the role of dia-
betes in long-term prognosis in this patient group compared to patients without
diabetes.
Purpose: To investigate whether the presence of diabetes affects the prognosis
in ventricular function in long-term follow-up.
Methods: We prospectively analyzed in a database, outpatients, previously sub-
mitted to percutaneous, surgical or clinical treatment. All patients had multivessel
disease and LVEF measures. The events considered were overall mortality, non-
fatal myocardial infarction, stroke and additional interventions.
Results: From January 2009 to January 2010 were selected 918 consecutive
patients, followed until May 2015. They were grouped into: G1, 266 diabetic pa-
tients with ventricular dysfunction, G2, 213 diabetic without dysfunction, G3, 213
patients without diabetes and without dysfunction and G4, 226 patients without
diabetes and with dysfunction. The mortality rate was 21.6%, 6.1%, 4.2% and
10.6% for Groups 1, 2, 3 and 4 respectively. (p<0.001). The incidence of nonfa-
tal myocardial infarction was 5.3%, 0.5%, 7.0% and 2.6% for groups 1, 2, 3 and
4 respectively (p<0.001). Stroke occurred at 0.40% 0.45%, 0.90% and 0.90% in
groups 1, 2, 3 and 4 respectively (p = NS). Further interventions occurred in 3.8%,
11.7%, 10.3% and 2.6% for groups 1, 2, 3 and 4 respectively (p<0.001).
Figure 1
Conclusion: In this sample, regardless of the treatment received, diabetes mel-
litus added higher risk of cardiovascular events in patients with coronary artery
disease and left ventricular dysfunction.
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Improvement of the cardiac hemodynamic performance among
dialysis patients with end-stage renal disease by active fluid
management modulation
M. Dekleva, Z. Paunic, N. Markovic-Nikolic, N. Dimkovic. University Clinical
Center Zvezdara, Department of Cardiology, Belgrade, Serbia
Background: Excessive extracellular volume (ECW) is one of the paradigms of
the end-stage renal disease (ESRD), and contributed to higher blood pressure
and cardiomyopathy among chronic dialysis patients. It was assumed that ECW
control guided by bioimpedance spectroscopy (BIS) measurement i.e. the con-
cept called Active fluid management (AFM) could lead to improved cardiac per-
formance compared to standard clinical assessment of their so-called “dry weight”
(DW).
Aims: Assessment and comparison of Doppler-echocardiographic indexes of car-
diac morphology and function in two groups of patients with (I) and without (II)
active fluid management (AFM) implementation before dialysis in 9 months follow
up.
Methods: BIS was performed by Body Composition Monitor (BCM) until the av-
erage weekly over- hydration had been in the target range (i.e. <15% of normal
extra cellular volume) and AFM was implemented throughout 9 months study
period (group I). In group II, BIS has been performed monthly without influence
on clinical assessment of patient’s DW. Two dimensional (2D) Doppler Echocar-
diography with spackle tracking was performed at start and after 9 months and
cardiac chambers diameters, volumes and functions were obtained as well as
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